Craft

Albumedix

Revenue

£26.1 M

FY, 2018

Albumedix Summary

Company Summary

Overview
Albumedix develops bio-therapeutics formulations for advanced drug and vaccine formulation intended to improve therapies for people with serious diseases. It offers recombumin, drug and vaccine stabilization, cell therapy formulation, drug conjugates, enabling the medical sector to formulate drugs for treatment of diseases.
Type
Private
Status
Active
Founded
2016
HQ
Nottinghamshire, GB | view all locations
Website
https://albumedix.com/
Cybersecurity rating
Sectors

Key People

  • Don Debethizy

    Don Debethizy, Chairman of Board of Directors

  • Phil Morton

    Phil Morton, Chief Technology Officer

  • Jonas S. Møller

    Jonas S. Møller, Chief Executive Officer

    • Stuart Woodward

      Stuart Woodward, Chief Manufacturing Officer

    LocationsView all

    2 locations detected

    • Nottinghamshire, England HQ

      United Kingdom

      59 Castle Blvd

    • Nottingham, England

      United Kingdom

      Mabel St

    Albumedix Financials

    Summary Financials

    Revenue (FY, 2018)
    £26.1M
    Net income (FY, 2018)
    £5.0M
    Cash (FY, 2018)
    £10.5M
    EBIT (FY, 2018)
    £5.5M

    Footer menu